Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

May 15, 2007 (Vol. 27, No. 10)

Development of Peptide Drugs Advances Briskly

Advantages for Protein-based Therapies Are Lower Toxicity and Better Efficacy

  • Emerging work in peptide drug development will begin paying off in the next few years as new compounds march toward clinical trials. Benefits, so far, include lower toxicity and greater efficacy than existing drugs and in some cases, new classes of compounds that are otherwise unavailable. Aileron Therapeutics ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.